Squalene, a naturally occurring organic compound, has found a unique application in the field of vaccine development. Known for its role in skin care and sterol biosynthesis, squalene is also a key ingredient in certain vaccine adjuvants. These adjuvants enhance the body's immune response to vaccines, making them more effective. This article explores the use of squalene in vaccine adjuvants, focusing on its role in improving immunogenicity and the development of influenza
vaccines.
Squalene-Based Adjuvants
In the realm of vaccines, adjuvants are substances that boost the immune response to an antigen. Squalene is not an adjuvant by itself, but it is used in combination with surfactants to create effective adjuvant formulations. One notable example is MF59, a proprietary adjuvant developed by Seqirus, which incorporates squalene in an oil-in-water emulsion. This formulation is used in influenza vaccines to enhance their immunogenicity.
MF59 was first developed in the 1990s by researchers at Ciba-Geigy and Chiron, companies that were later acquired by Novartis. The influenza vaccine business of Novartis was eventually acquired by CSL Bering, leading to the creation of Seqirus. MF59 is the first oil-in-water adjuvant to be commercialized with a seasonal influenza virus vaccine, marking a significant advancement in vaccine technology.
Mechanism and Benefits
The exact mechanism by which squalene-based adjuvants enhance the immune response is not fully understood. However, it is known that MF59 stimulates the production of CD4 memory cells, which are crucial for long-term immunity. The adjuvant is capable of activating a number of genes that overlap with those triggered by other adjuvants, although the specific receptors involved remain unidentified.
Despite the unknowns, the benefits of squalene-based adjuvants are evident. A 2009 meta-analysis of 64 clinical trials involving influenza vaccines with MF59 reported a good safety profile and suggested a clinical benefit over non-adjuvanted vaccines. The use of MF59 in vaccines has been associated with slightly lower risks of chronic diseases, without altering the rate of autoimmune diseases.
Safety and Controversies
Squalene's use in vaccines has been subject to scrutiny, particularly concerning its safety. However, extensive studies by the World Health Organization and the U.S. Department of Defense have confirmed that squalene is naturally occurring and safe in the concentrations used in vaccines. Since 1997, over 22 million flu vaccines containing squalene have been administered in Europe without significant adverse events.
In conclusion, squalene's role in vaccine development highlights its potential to enhance immunogenicity and improve vaccine efficacy. As research continues, squalene-based adjuvants may play an increasingly important role in the fight against infectious diseases.
